KNS 366
Alternative Names: KMO inhibitor - Kynos Therapeutics; KNS-366; Kynurenine 3-monooxygenase inhibitor - Kynos TherapeuticsLatest Information Update: 24 Apr 2024
At a glance
- Originator GlaxoSmithKline; University of Edinburgh
- Developer Kynos Therapeutics
- Class Anti-inflammatories; Benzoxazines; Benzoxazoles; Chlorine compounds
- Mechanism of Action Kynurenine 3-monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
- Preclinical Metabolic disorders
Most Recent Events
- 22 Apr 2024 Pharmacodynamics and Adverse events data from a phase I trial in Inflammation released by Kynos Therapeutics
- 23 Jan 2024 Kynos Therapeutics completes a phase I trial in Inflammation (In volunteers) in United Kingdom (IV) (ISRCTN10496020)
- 22 Dec 2022 Kynos Therapeutics plans a phase I trial for Inflammation (In volunteers) in United Kingdom (IV) (ISRCTN10496020)